Metabolic effects of oestrogen compounds in men with low testosterone

Metabolic effects of SERMs (Selective Oestrogen Receptor Modulators) in hypogonadal men

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000537358

Enrollment

Registered

2008-10-24

Start date

2008-02-06

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We aim to investigate the effects of raloxifene (SERM) in hypogonadal men on the growth hormone system and metabolism.

Interventions

Raloxifene (120 mg) as 2 oral tablets a day for 6 months

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

Male

Age

40 Years to 80 Years

Healthy volunteers

Inclusion criteria

Hypogonadism (prostate cancer patients on androgen deprivation therapy for at least 6 months)

Exclusion criteria

Androgen deprivation for less than 6 months, metastasis, cancer in other tissues than prostate, diabetes, kidney and liver disease, deep vein thrombosis

Outcome results